Biotech Reversal

Downside Projections

Nuremberg 2.0

For what seems the longest time, a recurring focus of this site has been the biotech sector.

Specifically, the IBB (ETF) and SPBIO (Index).

There’s good reason for that. In this update, we’ll go deeper into the downside opportunity.

Biotech Reversal:

SPBIO, topped out on February 9th this year. The IBB (ETF) topped one day later.

Both went on to form a Quarterly reversal bar; indicating a long term change in character.

Of the two, SPBIO has showed more weakness having posted monthly lower lows for three successive months.

That relative weakness over the IBB index, has resulted in focusing on the inverse of SPBIO; specifically the 3X inverse, LABD.

Working with leveraged inverse funds is only profitable on a short-term basis or when the underlying index is in a persistent down-trend.

Otherwise, typical market chop results in value erosion of the inverse fund (not advice, not a recommendation).

For the reasons discussed in the last section below (Nuremburg 2.0), we’re anticipating the index to have a sustained and persistent drop to much lower levels.

Downside Projections:

Going way back to Reminiscences of a Stock Operator and the Wyckoff Stock Market Institute training materials, both in their own way indicated a speculative position was only entered if there was sufficient potential.

Livermore’s 10-points or more and Wyckoff’s cause and effect

In Wyckoff’s case, the ’cause’ was price action congestion built up in the P&F chart.

The ‘effect’ was the resulting move.

Which brings us to now:

Many times on this site, we’ve said biotech has built up congestion in a way, when it reverses and begins its decline, price action itself will create lower targets.

We’ll present two charts showing how that’s happening.

The first P&F chart in this update and provided below, has a projected downside target for IBB around, 116 – 120 area:

Note, the downside is not to scale as the real location is far below the noted area.

Biotech IBB, then went on to post lower action. That in turn has resulted in an updated downside target:

Once again, the downside is not to scale.

It’s apparent, as IBB heads lower, it successively builds lower targets and it’s only (potentially) just getting started.

The weekly chart of IBB below, spells it out:

If and when IBB price action gets to the initial targets, it enters a congestion area that will (by that time) be over seven years wide.

If the trend is still down, that congestion in turn would target even lower levels.

The “-80%” interestingly enough, comes from a quote by Steven Van Metre at this link.

That 80% drop also corresponds to a downside Fibonacci (not shown) projection of 423.6%, on the above chart.

Nuremberg 2.0

This phrase has become so ubiquitous you can do a search for it.

So far, not a single mainstream financial site or YouTuber (still on that platform) has mentioned this fact in their analysis.

The speck injections are mass genocide and intended as such.

Two recent events resulting from injections are here and here.

If all of a sudden, injected pilots can’t fly (the first link), how are goods going to be transported?

Not generally known to the public, commercial air-transport is also used to haul freight (while carrying passengers).

Exactly how all of this (world crime) will break is unknown.

If and when it does, the result in the biotech sector as well as equities in general, could be successive air-pockets all the way down.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.